Cargando…

Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia

(1) Background: The treatment of peripheral arterial disease (PAD) is focused on improving perfusion and oxygenation in the affected limb. Standard revascularization methods include bypass surgery, endovascular interventional procedures, or hybrid revascularization. Cell-based therapy can be an alte...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaluvka, Frantisek, Ihnat, Peter, Madaric, Juraj, Vrtkova, Adela, Janosek, Jaroslav, Prochazka, Vaclav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731417/
https://www.ncbi.nlm.nih.gov/pubmed/33256237
http://dx.doi.org/10.3390/ijms21238999
_version_ 1783621895172653056
author Jaluvka, Frantisek
Ihnat, Peter
Madaric, Juraj
Vrtkova, Adela
Janosek, Jaroslav
Prochazka, Vaclav
author_facet Jaluvka, Frantisek
Ihnat, Peter
Madaric, Juraj
Vrtkova, Adela
Janosek, Jaroslav
Prochazka, Vaclav
author_sort Jaluvka, Frantisek
collection PubMed
description (1) Background: The treatment of peripheral arterial disease (PAD) is focused on improving perfusion and oxygenation in the affected limb. Standard revascularization methods include bypass surgery, endovascular interventional procedures, or hybrid revascularization. Cell-based therapy can be an alternative strategy for patients with no-option critical limb ischemia who are not eligible for endovascular or surgical procedures. (2) Aims: The aim of this narrative review was to provide an up-to-date critical overview of the knowledge and evidence-based medicine data on the position of cell therapy in the treatment of PAD. The current evidence on the cell-based therapy is summarized and future perspectives outlined, emphasizing the potential of exosomal cell-free approaches in patients with critical limb ischemia. (3) Methods: Cochrane and PubMed databases were searched for keywords “critical limb ischemia and cell therapy”. In total, 589 papers were identified, 11 of which were reviews and 11 were meta-analyses. These were used as the primary source of information, using cross-referencing for identification of additional papers. (4) Results: Meta-analyses focusing on cell therapy in PAD treatment confirm significantly greater odds of limb salvage in the first year after the cell therapy administration. Reported odds ratio estimates of preventing amputation being mostly in the region 1.6–3, although with a prolonged observation period, it seems that the odds ratio can grow even further. The odds of wound healing were at least two times higher when compared with the standard conservative therapy. Secondary endpoints of the available meta-analyses are also included in this review. Improvement of perfusion and oxygenation parameters in the affected limb, pain regression, and claudication interval prolongation are discussed. (5) Conclusions: The available evidence-based medicine data show that this technique is safe, associated with minimum complications or adverse events, and effective.
format Online
Article
Text
id pubmed-7731417
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77314172020-12-12 Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia Jaluvka, Frantisek Ihnat, Peter Madaric, Juraj Vrtkova, Adela Janosek, Jaroslav Prochazka, Vaclav Int J Mol Sci Review (1) Background: The treatment of peripheral arterial disease (PAD) is focused on improving perfusion and oxygenation in the affected limb. Standard revascularization methods include bypass surgery, endovascular interventional procedures, or hybrid revascularization. Cell-based therapy can be an alternative strategy for patients with no-option critical limb ischemia who are not eligible for endovascular or surgical procedures. (2) Aims: The aim of this narrative review was to provide an up-to-date critical overview of the knowledge and evidence-based medicine data on the position of cell therapy in the treatment of PAD. The current evidence on the cell-based therapy is summarized and future perspectives outlined, emphasizing the potential of exosomal cell-free approaches in patients with critical limb ischemia. (3) Methods: Cochrane and PubMed databases were searched for keywords “critical limb ischemia and cell therapy”. In total, 589 papers were identified, 11 of which were reviews and 11 were meta-analyses. These were used as the primary source of information, using cross-referencing for identification of additional papers. (4) Results: Meta-analyses focusing on cell therapy in PAD treatment confirm significantly greater odds of limb salvage in the first year after the cell therapy administration. Reported odds ratio estimates of preventing amputation being mostly in the region 1.6–3, although with a prolonged observation period, it seems that the odds ratio can grow even further. The odds of wound healing were at least two times higher when compared with the standard conservative therapy. Secondary endpoints of the available meta-analyses are also included in this review. Improvement of perfusion and oxygenation parameters in the affected limb, pain regression, and claudication interval prolongation are discussed. (5) Conclusions: The available evidence-based medicine data show that this technique is safe, associated with minimum complications or adverse events, and effective. MDPI 2020-11-26 /pmc/articles/PMC7731417/ /pubmed/33256237 http://dx.doi.org/10.3390/ijms21238999 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Jaluvka, Frantisek
Ihnat, Peter
Madaric, Juraj
Vrtkova, Adela
Janosek, Jaroslav
Prochazka, Vaclav
Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia
title Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia
title_full Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia
title_fullStr Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia
title_full_unstemmed Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia
title_short Current Status of Cell-Based Therapy in Patients with Critical Limb Ischemia
title_sort current status of cell-based therapy in patients with critical limb ischemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731417/
https://www.ncbi.nlm.nih.gov/pubmed/33256237
http://dx.doi.org/10.3390/ijms21238999
work_keys_str_mv AT jaluvkafrantisek currentstatusofcellbasedtherapyinpatientswithcriticallimbischemia
AT ihnatpeter currentstatusofcellbasedtherapyinpatientswithcriticallimbischemia
AT madaricjuraj currentstatusofcellbasedtherapyinpatientswithcriticallimbischemia
AT vrtkovaadela currentstatusofcellbasedtherapyinpatientswithcriticallimbischemia
AT janosekjaroslav currentstatusofcellbasedtherapyinpatientswithcriticallimbischemia
AT prochazkavaclav currentstatusofcellbasedtherapyinpatientswithcriticallimbischemia